For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Hydroxycarbamide, also known as hydroxyurea, is a medication used in sickle-cell disease, chronic myelogenous leukemia, cervical cancer, and polycythemia vera. In sickle-cell disease it decreases the number of attacks. It is taken by mouth.
Common side effects include bone marrow suppression, fevers, loss of appetite, psychiatric problems, shortness of breath, and headaches. There is also concern that it increases the risk of later cancers. Use during pregnancy is typically harmful to the baby. Hydroxycarbamide is in the antineoplastic family of medications. It is believed to work by blocking the making of DNA.
Scope of the Report:
This report focuses on the Hydroxycarbamide in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The classification of Hydroxycarbamide includes capsule and tablet, and the proportion of capsule in 2016 is about 63%, and the proportion is in decreasing trend from 2012 to 2016.
Hydroxycarbamide is widely used for sickle cell disease, cancer and other disease. The most proportion of Hydroxycarbamide is used for sickle cell disease, and the proportion in 2016 is 45%.
Asia Pacific is the largest supplier of Hydroxycarbamide, with a production market share nearly 59% in 2016.
Middle East and Africa is the largest consumption place, with a consumption market share nearly 36% in 2016. Following Middle East and Africa, Asia Pacific is the second largest consumption place with the consumption market share of 20%.
Market competition is not intense. Bristol Myers Squibb, Taj Pharma, Beijing Jialin Pharma, Qilu Pharmaceutical, Teva Pharma, Cipla, Zydus Cadila, United Biotech, Par Pharma, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
The worldwide market for Hydroxycarbamide is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
- Bristol Myers Squibb
- Taj Pharma
- Beijing Jialin Pharma
- Qilu Pharmaceutical
- Teva Pharma
- Zydus Cadila
- United Biotech
- Par Pharma
- Khandelwal Laboratories
- Alkem (Cytomed)
- Samarth Pharma
- VHB Life Sciences
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Market Segment by Applications, can be divided into
- Sickle Cell Disease
There are 15 Chapters to deeply display the global Hydroxycarbamide market.
Chapter 1, to describe Hydroxycarbamide Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Hydroxycarbamide, with sales, revenue, and price of Hydroxycarbamide, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Hydroxycarbamide, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Hydroxycarbamide market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Hydroxycarbamide sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source